# Irritable Bowel Syndrome FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/irritable-bowel-syndrome

> 2 upcoming FDA catalysts in irritable Bowel Syndrome: camlipixant (GSK) on Mar to Jun 2027 (topline data readout); camlipixant (GSK) on March 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 17, 2026 | [Eluxadoline primary completion](https://sec-api.dev/pdufa/eluxadoline) | ABBV | Irritable Bowel Syndrome | completed | "NCT03339128 (Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03339128)) |
| Aug to Nov 2026 | [Eluxadoline topline data readout](https://sec-api.dev/pdufa/eluxadoline) | ABBV | Irritable Bowel Syndrome | scheduled | "NCT03339128 (Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03339128)) |
| Mar to Jun 2027 | [Camlipixant topline data readout](https://sec-api.dev/pdufa/camlipixant) | GSK | Irritable Bowel Syndrome | scheduled | "NCT07519395 (A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07519395)) |
| March 2027 | [Camlipixant primary completion](https://sec-api.dev/pdufa/camlipixant) | GSK | Irritable Bowel Syndrome | scheduled | "NCT07519395 (A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07519395)) |

## Drugs

- [Eluxadoline](https://sec-api.dev/pdufa/eluxadoline) (ABBV)
- [Camlipixant](https://sec-api.dev/pdufa/camlipixant) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/irritable-bowel-syndrome.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Irritable Bowel Syndrome FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/irritable-bowel-syndrome

```bibtex
@misc{secapidev_indications_irritable_bowel_syndrome_20261116,
  title        = {Irritable Bowel Syndrome FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/irritable-bowel-syndrome}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_irritable_bowel_syndrome_20261116","title":"Irritable Bowel Syndrome FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/irritable-bowel-syndrome","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
